
In stock
Tirzepatide Research Peptide
Tirzepatide is a synthetic 39-amino-acid peptide based on the GIP sequence, carrying a C20 fatty diacid side chain, that acts at both the GIP and GLP-1 receptors. It is the active ingredient of two FDA-approved Eli Lilly prescription medicines. The research material on this page is neither of those medicines.
- Single Vial$30
- 5-Pack (5 vials)$26 per vial$130
- 10-Pack (10 vials)$21.50 per vial Lowest per vial$215
Ships from the United States within 1 business day, to the US and the UK and Europe. Laboratory research use only.
Certificate of analysisTirzepatide 20mg

- Batch
- N1-T20
- Purity
- 99.61% as reported by the lab
- Tested
- Lab
- Amino Metrics
Lab results
2 published certificates of analysis for Tirzepatide, newest first. Purity is as reported by the testing lab on each certificate. All lab results
| Strength | Batch | Purity | Test date | Lab | Certificate |
|---|---|---|---|---|---|
| 30 mg | N1-T30 | 99.96% | Freedom Diagnostics | Details of batch N1-T30 PDF of batch N1-T30 | |
| 20 mg | N1-T20 | 99.61% | Amino Metrics | Details of batch N1-T20 PDF of batch N1-T20 |
At a glance
- Strengths
- 10 mg
- 20 mg
- 30 mg
- Also known as
- LY3298176
- CAS number
- 2023788-19-2
- Molecular formula
- C225H348N48O68
- Molecular weight
- 4813 g/mol (FDA label: 4813.53 Da)
- Sequence
- Y-Aib-EGTFTSDYSI-Aib-LDKIAQ-K(gamma-Glu-2xAEEA-C20 diacid)-AFVQWLIAGGPSSGAPPPS-NH2 (39 residues; Lys20 acylated)
- PubChem CID
- 166567236
What tirzepatide is
Tirzepatide is a dual agonist of the GIP receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Eli Lilly developed it under the code LY3298176 1. A 2020 study by Lilly scientists and academic collaborators examined how it engages each receptor 1. The authors reported greater engagement of GIPR than GLP-1R, which they called imbalanced agonism. At GLP-1R they reported a preference for cAMP generation over beta-arrestin recruitment, which they called biased agonism 1. A 2022 cryo-electron microscopy and molecular dynamics study examined the structural basis of this pharmacology. Its authors concluded that the fatty acid modification, together with the amino acid sequence, determines how the molecule acts at the two receptors 2. These are cell-based and structural findings. Tirzepatide is related to retatrutide, which adds glucagon receptor activity, but the two have different sequences and masses.
Structure and chemical identity
According to its FDA label, tirzepatide is based on the GIP sequence. It contains 2-aminoisobutyric acid (Aib) at positions 2 and 13 and a C-terminal amide. The lysine at position 20 is attached to 1,20-eicosanedioic acid through a linker, which FDA's substance registry describes as a gamma-glutamic acid followed by two amino-ethoxy-ethoxy-acetic acid units. In PubChem, tirzepatide is CID 166567236: formula C225H348N48O68, molecular weight 4813 g/mol. The FDA label gives 4813.53 Da. The CAS number is 2023788-19-2. The C-terminal run of prolines matters for manufacture. During linear solid-phase synthesis, intermediates ending in Pro-Pro-Ser can form diketopiperazines, which leave double-amino-acid deletion impurities 3.
Regulatory status
FDA approved tirzepatide in two Eli Lilly prescription medicines: on May 13, 2022 (NDA 215866) and on November 8, 2023 (NDA 217806). The approved indications are set out in each medicine's FDA label, available through Drugs@FDA for NDA 215866 and NDA 217806. The tirzepatide sold here is neither medicine. No FDA approval covers its manufacture or quality, and it is sold only for laboratory research, never for use in people or animals.
Published research
The literature runs from receptor pharmacology to large trials, and the studies most useful for a laboratory are listed here by design.
- Receptor pharmacology (2020). Receptor occupancy modeling, signaling and internalization assays, and primary islet experiments 1.
- Structural biology (2022). Cryo-electron microscopy and molecular dynamics simulations of tirzepatide bound to its receptors 2.
- Process chemistry (2022). A mechanistic study of diketopiperazine formation during solid-phase synthesis, with control strategies 3.
- Population pharmacokinetics (2024). A model built from 19 pooled studies 4.
- Analytical method (2026). A stability-indicating HPLC method tested under acidic and basic hydrolysis, oxidative and photolytic stress 5.
Lilly's phase 3 programs for the approved medicines are named SURPASS and SURMOUNT. Their designs are registered on ClinicalTrials.gov, and this page does not summarize their results.
What is not known
Published clinical results cannot vouch for a powder synthesized elsewhere, whose identity, purity and stability have to be shown lot by lot. Synthesis route, counter-ion, peptide content and impurity profile can all differ between sources. The closest published work on degradation is the forced-degradation HPLC method above 5. A PubMed search found no study of how lyophilized research-grade tirzepatide changes during ordinary storage, so its solid-state degradation products and their rates of formation are undescribed.
Laboratory storage and handling
Store research tirzepatide as stated on the lot's certificate of analysis and product label. The FDA label of the approved medicine (NDA 217806) says to protect it from heat and light, but that instruction belongs to the approved medicine, not to research powder. To avoid condensation on the powder, bring a cold vial to room temperature before the seal is broken. The lot number and opening date belong in the lab record.
Quality testing
A certificate of analysis for tirzepatide should confirm identity by mass spectrometry, with a measured mass consistent with about 4813 Da. That result also distinguishes tirzepatide from retatrutide, which has a molecular weight of about 4731 g/mol. Reversed-phase HPLC is the standard purity method, and a stability-indicating method separates tirzepatide from its stress degradants 5. The certificate is more useful when it includes the chromatogram rather than a single percentage. Peptide content, counter-ion and water content explain the gap between the weight of powder and the amount of peptide. One impurity class is documented for this molecule: double-amino-acid deletions that arise from diketopiperazine formation during solid-phase synthesis 3. Material in which the fatty diacid side chain is missing or incomplete is a general concern for acylated peptides. The certificate should say whether the method looked for both.
Questions
Is research-grade tirzepatide the same as FDA-approved tirzepatide medicines?
No. The approved tirzepatide medicines are Eli Lilly products, made and released under their FDA approvals (NDA 215866 and NDA 217806). The material sold here shares the active ingredient's name and intended structure but is a laboratory reagent that FDA has not evaluated. It is not for human or animal use.
What does LY3298176 refer to?
LY3298176 is Eli Lilly's development code for tirzepatide. The 2020 receptor pharmacology paper by Lilly scientists gives both names together.
Which impurities are typical of synthetic tirzepatide?
Truncated sequences and molecules lacking the fatty diacid side chain are general concerns for an acylated peptide. A tirzepatide-specific one is the double-amino-acid deletion caused by diketopiperazine formation at the Pro-Pro-Ser end during solid-phase synthesis, which process chemists at Lilly have studied in detail.
Where can I buy Tirzepatide (tirz) online?
Here, at LotusPeptide. Tirzepatide is for sale in 10 mg, 20 mg and 30 mg vials, from $20, and ships from the United States within 1 business day to the US, the UK and Europe. Each batch's certificate of analysis is published on the lab results page. For 10, 50 and 100-vial packs, see wholesale. Tirzepatide is sold only for laboratory research, not for human or veterinary use.
Does LotusPeptide ship Tirzepatide to the UK and Europe?
Yes. Tirzepatide ships from the United States to the United Kingdom and 13 EU countries by UPS Worldwide Express: $55 flat for a standard package, typically 2 to 5 days in transit. Import VAT, duties and fees are paid by the recipient on delivery, and orders to the UK and Europe are paid in cryptocurrency at checkout. Details are on the UK and Europe page.
Is there a certificate of analysis for Tirzepatide?
Yes. 2 batch certificates of analysis are published for Tirzepatide. The newest, batch N1-T30 (30 mg), was tested by Freedom Diagnostics on Nov 12, 2026 and reports 99.96% purity. Each certificate links to the lab's PDF on the lab results page.
References
- Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020. pubmed.ncbi.nlm.nih.gov
- Sun B, Willard FS, Feng D, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci U S A. 2022. pubmed.ncbi.nlm.nih.gov
- Wang J, Berglund MR, Braden T, et al. Mechanistic Study of Diketopiperazine Formation during Solid-Phase Peptide Synthesis of Tirzepatide. ACS Omega. 2022. pubmed.ncbi.nlm.nih.gov
- Schneck K, Urva S. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT Pharmacometrics Syst Pharmacol. 2024. pubmed.ncbi.nlm.nih.gov
- Khalil HA, Hassanein NA, El-Yazbi AF, et al. A multimodal HPLC stability indicating approach for the estimation of Semaglutide and Tirzepatide in bulk, pharmaceutical dosage forms, and rat plasma: a six-edged sustainability appraisal. BMC Chem. 2026. pubmed.ncbi.nlm.nih.gov
This page summarizes published laboratory research and cites its sources. It is not medical advice and makes no claim that the compound treats, cures or prevents any condition. LotusPeptide sells it for laboratory research use only.
Shipping and returns
- Shipping
- Orders are processed and shipped within 1 business day. US orders typically arrive 1 to 3 business days after they ship.
- UK and Europe
- UPS Worldwide Express, $55 flat, typically 2 to 5 days in transit. Countries, VAT and duties
- Returns
- Returns are not accepted.
- Damaged or lost items
- Replacements and refunds are offered on damaged or lost items.